Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116634 | 0.90 | MAPT (0.43) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL4968403 | 0.88 | MAPT (0.56) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL4968406 | 0.88 | MAPT (0.56) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL6712490 | 0.83 | MAPT (0.51) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL14116635 | 0.82 | TERT (0.44) | MAPTALDH1A1GAA | |
| SCHEMBL6713011 | 0.80 | MCHR1 (0.54) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL14523950 | 0.80 | MAPT (0.48) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL14116494 | 0.80 | MAPT (0.48) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL13876933 | 0.78 | KMT2A (0.51) | MAPTRAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL28183332 | 0.78 | HCAR3 (0.65) | MAPTKMT2AMEN1ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | MAPT 4445/4885RAB9A 2415/4885LMNA 2120/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | MAPT 3892/4885RAB9A 1991/4885LMNA 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.